Joint Training and Research Program on Chromatin Dynamics and the DNA Damage Response
Acronym
aDDRess
Description of the granted funding
Defects in DNA repair trigger a number of devastating health complications ranging from developmental abnormalities to the premature onset of age-related diseases, including the metabolic syndrome, neurodegeneration and cancer. To counteract genome instability, cells have evolved a battery of DNA repair mechanisms ensuring that their genome remains functionally intact and is faithfully transmitted to progeny. Recent work reveals that DNA repair factors play additional roles in vital biological processes, including nucleosome remodeling, chromatin architecture, RNA biogenesis or the transcription activation of genes involved in cellular reprogramming and growth. These recent discoveries have pushed the DNA repair field forward and towards new grounds requiring a series of sophisticated functional and multidisciplinary approaches. Based on these novel scientific paths, we have carefully designed the “aDDRess” consortium on the basis of past excellence of the individual participants and their relevance to the proposed field. The action addresses a major research topic i.e. DNA damage in development and disease with great socioeconomic impact in Europe and direct relevance to human health. The objectives of the program are:
i. to create a European research platform of excellence in the field of DNA repair by integrating research from basic mechanisms to translational research applications,
ii. to establish a Network dedicated to the high-quality training of ESRs promoting their independent careers and future employment prospects,
iii. to transform our current successful, long-term collaborations into a stronger intellectual network and build durable links between the participating labs and the industry (SMEs). Understanding the relevance of genome maintenance pathways to human health will shed light onto the causal mechanisms of rare and widespread life-threatening diseases, including cancer.
Show moreStarting year
2019
End year
2023
Granted funding
GENEVIA TECHNOLOGIES OY
280 805.76 €
Participant
UNIVERSITE DE PARIS (FR)
274 802.04 €
Participant
NORGENOTECH AS (NO)
292 342.32 €
Participant
PANEPISTIMIO KRITIS (EL)
Participant
ETAIRIA DIACHIRISIS KAI ANAPTIXIS EPISTIMONIKOU KAI TECHNOLOGIKOU PARKOU KRITIS AE (EL)
Participant
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH)
281 276.64 €
Participant
FAKULTNI NEMOCNICE U SV. ANNY V BRNE (CZ)
234 871.56 €
Participant
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT)
261 499.68 €
Participant
SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI DI TRIESTE (IT)
Participant
UNIVERSITAET ZU KOELN (DE)
Participant
KLINIKUM DER UNIVERSITAET ZU KOELN (DE)
252 788.4 €
Participant
UNIVERSITE DE GENEVE (CH)
Participant
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE)
252 788.4 €
Participant
KAROLINSKA INSTITUTET (SE)
281 982.96 €
Participant
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL)
265 619.88 €
Participant
KOBENHAVNS UNIVERSITET (DK)
297 522 €
Participant
IDRYMA TECHNOLOGIAS KAI EREVNAS (EL)
486 035.28 €
Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR)
274 802.04 €
Participant
Amount granted
4 011 939 €
Funder
European Union
Funding instrument
Marie Skłodowska-Curie Innovative Training Networks (ITN)
Framework programme
Horizon 2020 Framework Programme
Call
Programme part
EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (5220 Fostering new skills by means of excellent initial training of researchers (5221 )
Topic
Innovative Training Networks (MSCA-ITN-2018Call ID
H2020-MSCA-ITN-2018 Other information
Funding decision number
812829
Identified topics
genes, genetics